A new glyco-biomarker for comprehensive evaluation of malignant potential in prostate cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 24659708
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Hirosaki University
• Principal Investigator: OHYAMA Chikara 弘前大学, 医学(系)研究科(研究院), 教授 (80282135)
• Co-Investigator(Kenkyū-buntansha): HATAKEYAMA Shingo 弘前大学, 医学研究科, 助教 (10400136) ; TSUBOI Shigeru 弘前大学, 医学研究科, 研究員 (20526727) ; MORI Kazuyuki 弘前大学, 医学研究科, 助教 (40266903) ; YONEYAMA Tohru 弘前大学, 医学研究科, 助教 (50587649) ; KOIE Takuya 弘前大学, 医学部附属病院, 講師 (60321965)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 前立腺癌 / バイオマーカー / 悪性度診断法 / 糖タンパク

Outline of Final Research Achievements

We newly established　a　monoclonal　antibody　against　core2　beta1,6-N-acetylglucosaminyltransferase(C2GnT).Using　this　monoclonal antibpdy, we immunohinstochemically evaluated relationship between C2GnT expression and biochemical recurrence of prostate cancer after radical prostatectomy.　C2GnT exprsssion was a significant and independent predictor of biochemical recurrence.　　We then developed a new assay system for C2GnT using post prostate massage urine sample by dot-blot method. C2GnT expression in urine sample detedced by this new assay system was a sinigicant and independent predictor for capsular invasion in prostate cancer. We now on our way to examine the potential of urine C2GnT expression as a predictor for PSA recurrence after radical prostatectomy.
Further validation study is warranted.

Free Research Field

泌尿器科学